Registration - Organization

Novartis Pharmaceuticals Canada Inc. / Andrea Marazzi, Novartis Country President Canada

Registration Information

Organization name: Novartis Pharmaceuticals Canada Inc.
Senior Officer Name: Andrea Marazzi, Novartis Country President Canada
Senior Officer Change History
Initial registration start date: 2010-05-04
Registration status: Active
Projected end date: No date provided
Registration number: 8870-2301

Associated Lobbying Activity Reports

Total number of Lobbying Activity Reports: 13

Lobbying Activity Reports - last 6 months: 2

Version 26 of 35 (2022-03-15 to 2022-05-09)

Registration versions:

Version 26 of 35 (2022-03-15 to 2022-05-09)

Lobbying Information

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Yes

Subject matters added through an Lobbying Activity Report:
Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
CC on an email message to department staff regarding Health Canada Approval of an important new therapy.	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical, Laboratory & Blood Services Division (PLBSD) will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative pharmaceutical treatments for BC citizens that require publicly funded access to these treatments, through various BC government programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology, Senior Citizens
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Hospitals
Letter of congratulations on outcome of October general provincial election to Premier Horgan (CC Minister of Health Dix.) Offered Novartis collaboration in addressing health related issues of concern to the provincial government	Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation	Health
Subject matters added through an Lobbying Activity Report:
ADM Moneo was copied on an email to PLBSD senior Formulary Management staff requesting an update on the Drug Review Process status for Kesimpta used to treat Relapsing Remitting Multiple Sclerosis. The email communication requested copies of documents related to Pharmacare's Drug Review Process for Kesimpta (documents requested were; 1) the draft Drug Benefit Council Recommendation, and 2) Clinical Practice Reviews for Kesimpta.) The email request also included the following PDF documents as attachments; a copy of the November 20, 2020 submission cover letter from Novartis to PLBSD requesting Kesimpta be included as a Pharmacare benefit for BC patients with RRMS. The email message also included a PDF copy of the March 2021 CADTH Final Recommendation indicating that provincial drug plans should add Kesimpta as a public drug plan benefit. The message also indicated that all other western provinces have or will soon add Kesimpta as an eligible public drug plan benefit for RRMS. Saskatchewan Drug Plan benefit as of May 1st, Alberta Heath Drug Plan Benefit as of May 1st; Manitoba Provincial Drug Plan Benefit; June 1st (per Manitoba Drug Benefits Formulary Bulletin #118, page 5)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
ADM Moneo was copied on an email to PLBSD senior Formulary Management staff requesting an update on the Drug Review Process status for Kesimpta used to treat Relapsing Remitting Multiple Sclerosis. The email communication requested copies of documents related to the Pharmacare Drug Review for Kesimpta (i.e. draft Drug Benefit Council Recommendation and Clinical Practice Reviews.) The email request also included attached PDF documents; a copy of the November 20, 2020 submission letter from Novartis to PLBSD requesting inclusion of Kesimpta as a Pharmacare benefit for BC patients with RRMS. Attachments to the email message also included the March 2021 CADTH Final Recommendation indicating that provincial drug plans should add Kesimpta as a public drug plan benefit. The email copied to ADM Moneo indicated that all other western provinces either already have, or are adding Kesimpta as an eligible public drug plan benefit, to treat RRMS (ref. plans covering Kesimpta as follows; Saskatchewan; May 1st, Alberta; May 1st; Manitoba; June 1st (Manitoba Drug Benefits Formulary Bulletin #118, page 5)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meeting request to explore and understand BC Ministry of Health challenges, barriers, timelines and possible solutions to enable patients to be treated with innovative specialized therapies at sites in BC. (BC patients currently do not have access or are traveling to out-of-province jurisdictions to receive some innovative therapies.)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health

BC Ministries/Provincial Entities

Fraser Health Authority
Health
Innovate BC
Member(s) of the BC Legislative Assembly
Providence Health Care Society
Provincial Health Services Authority
Vancouver Coastal Health Authority
Vancouver Island Health Authority

Organization Details

Senior Officer Name and Position during the Period of this Registration

Christian Macher, Country President & Oncology GM Canada

Organization Contact Information

Novartis Pharmaceuticals Canada Inc.

Address:
385 Boul Bouchard.
Dorval, QC H9S 1A9
Canada

Telephone number: 604-218-9838
Fax number: 514-631-0307

Description of Activities

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Contributors to the Lobbying Activity

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of the organization that has a direct interest in the outcome of the lobbying activity.

Government Funding in the Last 12 Months

No government funding was requested or received within the preceding 12 months.

Coalition Members Information

Novartis Pharmaceuticals Canada Inc. is not a coalition member.

Affiliates with a Direct Interest in the Outcome

Novartis Pharmaceuticals Canada Inc. does not have any affiliates that could have a direct interest in the outcome of the lobbying activities

Other Persons or Organizations with Direct Interests

The activities of Novartis Pharmaceuticals Canada Inc. are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.

Lobbyists Details

Lobbyists Employed by this Organization

Lobbyist

Contributions

Caroline Barber
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No